GB10

Phase 1Small molecule

SShenzhen Kexing Pharmaceutical Co., Ltd.

GB10 is one of 39 small molecule programs targeting Age-Related Macular Degeneration. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Age-Related Macular DegenerationActive, not recruiting

Age-Related Macular DegenerationPhase 1

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Eylea

Regeneron

Phase 3

44 2

Lucentis

Roche

Phase 3

64 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Retaane

AAlcon Research

Phase 3

5 8

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

2 9

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 10

Aquasol E

NNational Eye Institute (NEI)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Age-Related Macular Degeneration

NCT07406438

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Not yet recruiting·SShenzhen Kexing Pharmaceutical Co., Ltd.·Phase 1·NCT07406438·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GB10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GB10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GB10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen Kexing Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShenzhen Kexing Pharmaceutical Co., Ltd.

GB10

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

References

Drug Info

Quick Facts

Related News